The estimated Net Worth of Douglas J Swirsky is at least $155 millier dollars as of 14 September 2021. Mr. Swirsky owns over 25,000 units of Cellectar Biosciences Inc stock worth over $52,250 and over the last 12 years he sold CLRB stock worth over $0. In addition, he makes $102,354 as Independent Chairman of the Board at Cellectar Biosciences Inc.
Douglas has made over 2 trades of the Cellectar Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of CLRB stock worth $26,000 on 14 September 2021.
The largest trade he's ever made was buying 50,000 units of Cellectar Biosciences Inc stock on 29 January 2019 worth over $31,500. On average, Douglas trades about 2,885 units every 37 days since 2013. As of 14 September 2021 he still owns at least 25,000 units of Cellectar Biosciences Inc stock.
You can see the complete history of Mr. Swirsky stock trades at the bottom of the page.
Douglas J. Swirsky is Independent Chairman of the Board of the Company. Mr. Swirsky was appointed as a director of Cellectar in April 2017 and Chairman of our Board in August 2017. Since November 2018, Mr. Swirsky has served as President, Chief Executive Officer, and a director of Rexahn Pharmaceuticals; having previously served as Rexahn’s President and Chief Financial Officer from January 2018 until his appointment as CEO. Prior to Rexahn, Mr. Swirsky served as President and Chief Executive Officer of GenVec, Inc., a clinical-stage biopharmaceutical company, from 2014 to June 2017. From 2006 through 2014, Mr. Swirsky served as Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary of GenVec. Prior to joining GenVec in September 2006, Mr. Swirsky worked at Stifel Nicolaus where he served as a Managing Director and the Head of Life Sciences Investment Banking. Mr. Swirsky previously held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason. His experience also includes positions in public accounting and consulting. Mr. Swirsky received his undergraduate degree in business administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a Certified Public Accountant and a CFA® charterholder. Within the past five years, Mr. Swirsky has also served on the board Fibrocell Science, Inc., Pernix Therapeutics Holdings, Inc. and GenVec, Inc. Our Board concluded that Mr. Swirsky should serve as a director and member of Compensation Committee along with Nominating and Corporate Governance Committee because of his distinguished career in financial services and corporate management, including his investment banking experience and his experience serving as a principal executive officer and principal financial officer.
As the Independent Chairman of the Board of Cellectar Biosciences Inc, the total compensation of Douglas Swirsky at Cellectar Biosciences Inc is $102,354. There are 6 executives at Cellectar Biosciences Inc getting paid more, with James Caruso having the highest compensation of $934,460.
Douglas Swirsky is 50, he's been the Independent Chairman of the Board of Cellectar Biosciences Inc since 2017. There are 8 older and 3 younger executives at Cellectar Biosciences Inc. The oldest executive at Cellectar Biosciences Inc is Frederick Driscoll, 69, who is the Independent Director.
Douglas's mailing address filed with the SEC is C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932.
Over the last 10 years, insiders at Cellectar Biosciences Inc have traded over $1,263,511 worth of Cellectar Biosciences Inc stock and bought 1,917,793 units worth $3,966,598 . The most active insiders traders include Austin W & Greenhouse David..., Investment Company, Inc. Awm et John Neis. On average, Cellectar Biosciences Inc executives and independent directors trade stock every 50 days with the average trade being worth of $126,821. The most recent stock trade was executed by Douglas J Swirsky on 14 September 2021, trading 25,000 units of CLRB stock currently worth $26,000.
cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p
Cellectar Biosciences Inc executives and other stock owners filed with the SEC include: